Two large, independent human immunodeficiency virus type 1 resistance databases containing . 7700 reverse-transcriptase (RT) sequences were used to analyze the epidemiology of amino acid substitutions at codons 44 and 118, which confer moderate lamivudine resistance in the presence of zidovudine resistance. As expected, E44A/D and V118I mutations were strongly associated with M41L, D67N, L210W, and T215Y but also with other mutations, including K43E/N/Q, T69D, V75M, H208Y, R211K, and K219R. Both E44D and V118I were more frequently associated with stavudine and didanosine than with zidovudine and lamivudine treatment. However, selection of E44A/D and V118I was also detected in association with a switch to other nucleoside RT inhibitors, including zalcitabine and abacavir. Site-directed mutagenesis confirmed that 44D and 118I can decrease phenotypic susceptibility not only to lamivudine but also to most other nucleoside analogues, particularly stavudine and abacavir. Thus, substitutions at RT codons 44 and 118 have broad implications in nucleoside RT inhibitor resistance in the setting of several nucleoside-associated mutations.
Development of drug resistance is a major cause for failure of anti-human immunodeficiency virus type 1 (HIV-1) therapy in patients adherent to treatment [1] . Following the demonstration that drug susceptibility data can be used to improve the response to treatment [2] , antiretroviral resistance testing is rapidly becoming an integral part of the clinical management of HIV-1 infection [3] . Patient-derived HIV-1 pol sequences can be amplified by polymerase chain reaction and inserted into a correspondingly deleted vector to yield a recombinant HIV-1, which is cultured in the presence of HIV-1 reverse-transcriptase (RT) inhibitors and protease inhibitors to measure phenotypic drug susceptibility in vitro [4, 5] . A more practical and less costly approach is to sequence the RT and protease pol regions directly and predict drug resistance on the basis of the specific mutations known to confer resistance in vitro [6] . Accordingly, many HIV care units are using genotypic rather than phenotypic assays. Clearly, the reliability of these genotypic resistance assays depends on the availability of large and up-to-date data sets comparing genotype and phenotype with clinical outcomes. Indeed, along with the continual enlargement of such genotypic-phenotypic resistance databases, new resistance mutations and mutational patterns are discovered and are included in an increasingly complex set of genotype interpretation rules.
An example of this is the recent finding that RT mutation E44A/D and/or V118I can confer moderate resistance (4-50-fold) to lamivudine, when present in the context of zidovudine resistance mutations (M41L, D67N, K70R, L210W, T215Y/F, and/or K219E/Q) [7] . These have recently been termed "thymidine analogue mutations" by some investigators, on the basis of evidence that a second thymidine analogue RT inhibitor (stavudine) also selects for them in vivo [8, 9] . However, because they now appear to be involved in resistance to a number of nucleoside analogues [10] , including abacavir [11] , nucleoside-associated mutations (or NAMs) might be a more appropriate term. The 44A/44D/118I mutational pattern thus appears to be an alternative pathway to lamivudine resistance, because lamivudine typically and rapidly selects for a well-known single mutation (M184V/I) conferring high-level (. 100-fold) lamivudine resistance [12] . However, a recent survey has shown that both E44D/A and V118I, although not detected in drug-naive patients, may be present in subjects who were not treated with lamivudine [13] , which raises the possibility that the role of these amino acid substitutions in RT inhibitor resistance is more complex. To address this issue, we have used 2 independent relational HIV-1 treatment/resistance mutation databases with a total of . 7700 RT sequences and have performed site-directed mutagenesis and phenotypic resistance studies. 
Materials and Methods
Databases and genotypic antiretroviral resistance testing. The first database was created and queried with Borland dBASE IV, version 2.0, at the HIV Monitoring Service of the University and Hospital of Siena, Italy (HIV-SMS), where an HIV-1 genotyping service has been established since 1996. Plasma RNA extraction and amplification and infrared sequencing of the RT region spanning aa 1-229, as performed with a sequencer (model 4000L; Licor) at this facility, have been described elsewhere [14] . At the time of analysis, the HIV-SMS database contained 3467 HIV-1 RT sequences obtained from a total of 1927 patients. Treatment history data were available for 3096 sequences obtained from 1729 patients, including 262 drug-naive and 1467 pretreated subjects. The second database was developed and queried with Oracle at the British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada (BC CfE). At the BC CfE, RT sequences were obtained on either an ABI 373 or an ABI 3700 sequencer (Applied Biosystems). At the time of analysis, this database contained 4287 HIV-1 RT sequences obtained from a total of 1642 patients, including 647 drugnaive and 995 pretreated patients, all with known treatment history. For both databases, the associations among mutations and between mutations and treatment were estimated by calculating both x 2 -associated P values and odds ratios with 95% confidence intervals in 2 £ 2 tables. P , :05 was considered to be significant.
Site-directed mutagenesis and phenotypic susceptibility assay. Mutations were generated in the RT gene of HXB2, a wild-type laboratory HIV-1 strain, with use of the QuikChange site-directed mutagenesis kit (Stratagene Cloning Systems). Phenotypic susceptibility analysis was done with the recombinant virus assay approach, as described by Hertogs et al. [4] , with modifications, as described by Pauwels et al. [15] (Antivirogram; Virco). In brief, protease and RT coding sequences were amplified with HIV-1-specific primers from DNA plasmids containing mutated RT genes. After homologous recombination of amplicons into a protease-and RT-deleted proviral clone, the resulting recombinant viruses were harvested, titrated, and used for in vitro testing of susceptibility to antiretroviral drugs. The results of this analysis are expressed as fold change values, reflecting the micromolar fold increase in mean IC 50 of a particular drug when tested with a mutant recombinant virus, relative to the mean micromolar IC 50 of the same drug obtained when tested with a reference wild-type virus isolate (HIV-1 IIIB/LAI ).
Results
The mutant RT codons 44A, 44D, and 118I were present in 31 (0.9%), 186 (5.4%), and 449 (12.9%) sequences, respectively, in the HIV-SMS database (n ¼ 3467) and in 103 (2.4%), 234 (5.5%), and 473 (11.0%) sequences, respectively, in the BC CfE database (n ¼ 4287). Of the sequences containing 44A or 44D, 28 (90.3%) and 108 (58.1%), respectively, also contained 118I in the HIV-SMS database. The corresponding figures for the BC CfE database were 70 (68.0%) and 157 (67.1%). By contrast, only 30.3% and 48.0% of the sequences with 118I also contained 44D or 44A in the HIV-SMS and BC CfE databases, respectively. Of interest, the overall prevalence of the 3 mutant codons increased during the time period considered in the HIV-SMS but not in the BC CfE database, particularly for V118I (P , :0001, x 2 test for trend; figure 1 ). However, the overall patient exposure to nucleoside RT inhibitors (NRTIs) was higher for the BC CfE database than for the HIV-SMS database, especially before 1999 (figure 2).
The association between each mutant and single RT mutations is shown in figure 3 . RT mutations considered included those detected in .1% of the sequences and having .2-fold increased frequency in the presence of > 1 of the 3 mutant codons of inter- est. The patterns obtained with the 2 databases were remarkably similar. The linkage between 44A/44D/118I and NAMs was marked for M41L, D67N, L210W, and T215Y (P ¼ 10 210 to 10 2100 in both databases). At codon 219, both 44D and 118I showed a stronger association with an alternative mutant (K219R; P , 10 230 ) than with the canonical zidovudine resistance mutations K219E and K219Q. Of note, there was no significant association with K70R, because the frequency of 118I and 44A/D in the presence of 70R was comparable to or lower than, respectively, the frequency in its absence (data not shown). Likewise, the ratio between the frequency of 44A/44D/118I in the presence of the typical lamivudine resistance mutation M184V and in its absence ranged only from 1.24 to 1.47. However, 44A/44D/118I were significantly linked (P ¼ 10 26 to 10 2100 ) with other nucleoside mutations, including well-characterized nucleoside resistance mutations (i.e., T69D, V75M, and, to a lesser extent, L74V) and possible polymorphisms (i.e., H208Y and R211K). The association with some mutations typically selected by non-NRTIs (K101E, V108I, Y181C, and G190A) was likely indirect, reflecting the concomitant use of this antiretroviral class by patients with treatment failure. Finally, different mutant amino acids at position 43 were detected in strong association (P ¼ 10 220 to 10 2100 ) with the alternative E44A and E44D mutants (K43E and K43Q/N, respectively).
The association between 44A/44D/118I and treatment history was then analyzed by use of the RT sequences obtained from patients for whom the treatment history was available (a subset of 3096 sequences from 1729 patients in the HIV-SMS database and the whole BC CfE database). These included 2462 pretreated (median duration, 33 months; range, 4-128 months) and 909 drug-naive patients. Codons 118I, 44D, and 44A were detected in 36 (4.0%), 11 (1.2%), and 0 sequences, respectively, from drug-naive patients. However, in all but one (2.1%) case, several accompanying drug resistance mutations were detected, indicating that drug-resistant HIV-1 variants had been acquired by these subjects and confirming that 44A/44D/118I are selected by antiretroviral treatment. Indeed, in the HIV-SMS database, the prevalence of the 3 mutations increased significantly with increasing numbers of NRTIs used (P , 10 25 , P , 10 29 , and P , 10 224 for 44A, 44D, and 118I, respectively, when sequences derived from subjects treated with , 4 and . 3 NRTIs were compared; x 2 test). However, there was no such clear association in the BC CfE database (data not shown). The population of sequences obtained from the pretreated subjects was then used to compute the association between 44A/44D/118I and single NRTIs or NRTI pairs (figure 4). In the HIV-SMS database, both types of analysis revealed that the E44D and V118I mutations were more often associated with stavudine or didanosine than with zidovudine or lamivudine treatment. Because of the low number of occurrences, no particular association of any NRTI with E44A was evident, although the mutation was more prevalent in the lamivudine group. Of note, zidovudine therapy appeared to be minimally implicated, if at all, in selection of E44D and V118I. Indeed, zidovudine and lamivudine were significantly associated with E44D and V118I only when coupled with didanosine and stavudine, respectively, but not when used together. On the other hand, analysis of the BC CfE database confirmed that zidovudine and lamivudine were not the drugs most often associated with 44D and 118I but failed to corroborate a prominent role for stavudine in selection of these mutations. Selection of 44A appeared to be more likely with use of zidovudine, didanosine, zalcitabine, and zidovudine + lamivudine than with use of other NRTIs and NRTI pairs in this database, although confidence intervals were large. Incidentally, this analysis also showed that BC CfE patients more often received paired NRTI treatment than did HIV-SMS patients (see percentages in figure 4) .
Next, the databases were queried for multiple sequences from the same subject showing a shift from the absence to the presence of 44A/44D/118I temporally associated with an NRTI treatment change. There were 129 cases meeting these criteria (table 1) , with a median time of 7 months (range, 2-46 months) between the 2 genotypic tests. In agreement with the HIV-SMS data shown above, stavudine and/or didanosine were the only new NRTI(s) introduced concomitant with selection of 44A/44D/118I in 63 cases (48.8%), as opposed to 12 cases (9.3%) with zidovudine and didanosine or lamivudine (P , :0001, x 2 test). Overall, stavudine and/or didanosine were part of the new NRTI regimen in 100 cases (77.5%). Again, the association between 44A/44D/ 118I and stavudine use was more evident in the HIV-SMS than in the BC CfE database (data not shown). Of interest, there were several cases each of selection of 44A/44D/118I in association with introduction of zalcitabine or abacavir as the only new NRTI.
Finally, a panel of site-directed mutants was constructed, to analyze the contribution of E44D and V118I to drug resistance in vitro (table 2) . These data were interpreted with use of the biologic cutoff values recently defined in the Antivirogram assay [16] . Although neither 44D nor 118I affected the sensitivity to any of the NRTIs on its own, addition of either mutation to the highly associated NAM background of 41L/67N/210W/215Y (plus an R211K polymorphism) resulted in an increase in stavudine resistance to or above the cutoff of normal stavudine susceptibility. The level of stavudine resistance was higher when both 44D and 118I were present. Of interest, whereas addition of a T69D mutation further increased stavudine resistance, the presence of the typical lamivudine-selected M184V mutation decreased stavudine resistance. There were minor effects of 44D and/or 118I on didanosine and zalcitabine susceptibility, which remained below the biologic cutoff [16] , unless (for didanosine only) the T69D or M184V mutation was concomitantly present. Conversely, the susceptibility to abacavir was markedly decreased in the presence of 44D and/or 118I, with an additive effect, as in the case of stavudine. In fact, the occurrence of both mutations conferred a level of resistance to abacavir comparable to that measured in the presence of the M184V substitution.
Discussion
Our results confirm that E44A/D and V118I substitutions in HIV-1 RT are selected by antiretroviral therapy and are strongly associated with most of the NAMs originally described as being responsible for resistance to thymidine analogues (zidovudine and stavudine), particularly M41L, D67N, L210W, and T215Y. The prevalence of the 3 mutant codons in this work was somewhat lower than that reported in 2 recent analyses of clinical data sets [7, 13] , but the relative proportion of the 3 substitutions was remarkably similar in the 3 studies. A larger representation of sequences collected earlier in the antiretroviral era and a lower prevalence of heavily NRTI-experienced patients in our databases may account for this difference. Accordingly, the frequency of the 3 mutants was significantly associated with the number of NRTIs used in the HIV-SMS database and in a previous report [13] .
Although the occurrence of E44A/D and/or V118I mutations in the context of zidovudine resistance was first described as an alternative pathway to lamivudine resistance [7] , several observations suggest that lamivudine alone does not effectively select for these mutations. First, about one-fifth of the sequences including 44A/D and/or 118I in our databases were derived from patients who had never been treated with lamivudine. Second, none of the 3 mutations appears to substitute for the typical M184V mutation conferring high-level resistance to lamivudine. Indeed, they were even more prevalent in the presence of M184V than in its absence, both in our study and in a previous report [13] , despite the fact that they do not increase lamivudine resistance in genomes carrying the M184V mutation [7] . In addition, selection of the M184V substitution by lamivudine in HIV-1 genomes already carrying 44A/D and/or 118I has been described [13] .
The systematic analysis of the association between RT mutations and NRTI treatment in the HIV-SMS database revealed that, of the NRTIs, stavudine and didanosine were, by far, the most commonly associated with the E44D and V118I substitutions. By contrast, zidovudine and lamivudine had a much lower [15, 16] . Dashes (-) indicate no change with respect to consensus B; fold resistance values represent means of > 2 separate experiments. Abc, abacavir; ddC, zalcitabine; ddI, didanosine; d4T, stavudine; 3TC, lamivudine; Zdv, zidovudine. association with these mutations. The overall low prevalence of the E44A mutation in both databases did not allow us to establish whether it has a particular association with any NRTI. The choice between the E44A and E44D substitutions appeared to be linked to the preceding amino acid at position 43 in the RT. Substitutions at this position are also likely to be drug selected, because 43E/N/Q substitutions are virtually absent in sequences obtained from drug-naive patients (data not shown). Also of note, the only zidovudine resistance mutation not significantly associated with 44D and 118I was the K70R substitution, which is also less often selected by stavudine [9] and less involved in phenotypic stavudine resistance [17] . However, the same analysis of the BC CfE data confirmed that neither zidovudine nor lamivudine has a particularly relevant association with the substitutions at codons 44 and 118 but also failed to detect stavudine as the NRTI most associated with the E44D and V118I mutations. Because both databases started data collection in 1996 and are comparable in size, any different result obtained from parallel analysis may have derived from different treatment scenarios at the 2 geographic sites. Overall, the treatment strategy at BC CfE was more aggressive than that at HIV-SMS, resulting in a more pronounced exposure to the NRTIs, which in turn may have rendered the population less suitable to reveal associations between drugs and mutations. For example, the prevalence of use of any NRTI pair was higher at BC CfE than at HIV-SMS, except for the zidovudine + didanosine combination, and this more aggressive approach to therapy started much earlier at BC CfE (see figures 2 and 4). Of note, the far more rapid uptake of stavudine at BC CfE than at HIV-SMS was the most relevant treatment difference between the 2 sites. Indeed, in both databases, the role of stavudine and didanosine in selection of the 44D and 118I mutations was corroborated by the longitudinal analysis of a subset of patients who switched their NRTI(s) concomitant with a shift from a wild-type to a mutant virus population. Although stavudine and/or didanosine were the new NRTI(s) in most of these cases, other inhibitors, including zalcitabine and abacavir, were involved in the remaining cases, suggesting that 44D and 118I may play a broader role in NRTI resistance. This observation with abacavir was particularly relevant, because this recently introduced compound was, by far, the least used in our study populations. Although prospective analysis of a larger group of subjects at their initial antiretroviral treatment could help address this issue, it is indeed noteworthy that site-directed mutants containing 44D and/or 118I showed significantly decreased susceptibility to abacavir.
Site-directed mutagenesis data confirmed that both the E44D and V118I substitutions decrease susceptibility to stavudine in the presence of a common cluster of NAMs (41L/67N/210W/ 215Y). Of interest, a synergistic effect of the 2 substitutions was seen with stavudine resistance but was not seen with lamivudine resistance [7] . The extent of phenotypic resistance conferred by the 44D/118I pathway appears to be higher for lamivudine than for stavudine. However, it should be noted that comparable phenotypic fold resistance levels may have different implications for different drugs. Indeed, very high levels (. 100-fold) of resistance to lamivudine but not to stavudine are observed in in vitro phenotypic resistance assays. Furthermore, even phenotypic resistance below the biologic cutoff [16] may be significant for some drugs in some circumstances. In light of this, an integration of multiple databases (genotype-phenotype, genotype-clinical outcome, genotype-treatment history) could help define a genotype interpretation system to be used with increasing reliability in clinical practice. Furthermore, we anticipate that this information will be useful for enhancement of the accuracy of artificial intelligence systems, such as the virtual phenotype [18] , designed to predict phenotype from genotype.
